Search results (106)
« Back to NewsIneos Oxford Institute makes award to OVG project tackling antimicrobial resistance
28 October 2024
Awards & Appointments Vaccinology
The Ineos Oxford Institute for antimicrobial research (IOI) has awarded over £2m to six projects across the University of Oxford focused on developing new solutions to tackle antimicrobial resistance (AMR), including one at the Oxford Vaccine Group.
Typhoid vaccine trial confirms sustained protection for older children
10 October 2024
Clinical Trials Informing Policy Publication Research Vaccinology
A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.
Launch of new podcast series Trusting the Science
19 September 2024
The Oxford Vaccine Group is celebrating 30 years of life-saving vaccine development with the release of a new podcast series of conversations called Trusting the Science. This is the second series of The Oxford Colloquy - discourses hosted by Professor Sir Andrew Pollard who has been Director of the group for over 20 years - and each episode delves into the crucial role that science plays in our understanding of health and immunity.
Oxford scientists launch first-in-human vaccine trial for deadly Marburg virus
12 July 2024
Clinical Trials Recruitment Research Vaccinology
Scientists at the University of Oxford have launched a new clinical trial to test a vaccine to protect people against deadly Marburg virus.
New trial launches for two-in-one vaccine to prevent RSV and hMPV
12 July 2024
Children's Health Clinical Trials Research Vaccinology
Scientists at the University of Oxford have launched a phase 1 study to test two investigational mRNA vaccines: one for both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and a second for RSV alone in infants aged five to eight months old. The vaccines are being developed by Moderna.
Professor Teresa Lambe OBE elected to the Fellowship of the Academy of Medical Sciences
21 May 2024
Awards & Appointments Department Public Engagement Vaccinology
Professor Teresa Lambe OBE, Calleva Head of Immunology at the Oxford Vaccine Group, and Principal Investigator at the Pandemic Sciences Institute, has been elected a Fellow of the Academy of Medical Sciences, one of the most prestigious awards in the field.
Ground-breaking study reveals how COVID-19 vaccines prevent severe disease
3 May 2024
COVID-19 Clinical Trials Publication Research Research Methods Vaccinology
A landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.
Oxford hosts Belgian vaccine experts
28 March 2024
Department General Vaccinology
Researchers from Oxford Vaccine Group and the Pandemic Sciences Institute welcomed a delegation of vaccine researchers from Belgium to further UK-Belgian collaboration on vaccine development and manufacture.
Advancing a malaria vaccine for better global health outcomes
20 March 2024
Department General Vaccinology
Professor Sue Ann Costa Clemens CBE, Chair of Global Health at the Department of Paediatrics and Head of Oxford Latam Research Group – a collaboration between Oxford and Brazil, aimed at strengthening our commitment to global health – met with His Excellency Antonio Patriota, Brazilian Ambassador to the UK, to discuss the co-development of a Malaria vaccine and advance public health outcomes in Brazil.
New trial to study how the human immune system adapts to ‘tolerate’ malaria parasites
18 March 2024
Clinical Trials Research Research Methods Vaccinology
Scientists at the University of Oxford and the University of Edinburgh have launched a pioneering study that examines how the immune system responds to repeated malaria infections. The BIO-004 study is being run in partnership between the Department of Biochemistry (Draper Lab, based in the Kavli Institute for Nanoscience Discovery), the University of Edinburgh (Spence Lab, Institute of Immunology and Infection Research) and the Oxford Vaccine Group (part of the Department of Paediatrics). BIO-004 will provide a unique insight into how the immune system adapts over the first few malaria infections of life, learning to tolerate malaria parasites and developing natural immunity to severe illness.
Oxford University Professors to lecture on new course in 'Translational Science' at three Brazilian institutions
1 February 2024
Department Research Methods Teaching University Vaccinology
The Department of Paediatrics at the University of Oxford, has entered into an agreement with three Brazilian Universities, to contribute to the delivery of an undergraduate course in ‘Translational Science’, starting in 2024.
FCDO Minister meets with vaccine researchers
25 January 2024
COVID-19 Department Public Engagement University Vaccinology
Researchers from the Department of Paediatrics today welcomed the Rt Hon Andrew Mitchell MP, Minister for Development and Africa, to the laboratories and clinics of several of its vaccine development groups.
First in-human vaccine trial for Nipah virus
11 January 2024
Clinical Trials Immunology Research Vaccinology
The University of Oxford has launched a new clinical trial to test a vaccine against the deadly Nipah virus.
OVG receives £7.8 million in research funding to fight pandemic and epidemic threats
12 December 2023
Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of £7,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential.
New campaign by Oxford Vaccine Group hopes to boost jab numbers
8 December 2023
COVID-19 Clinical Trials Public Engagement Vaccinology
Experts have launched a new campaign in a bid to boost waning vaccine uptake by giving people more information about how clinical trials work. Researchers hope to alleviate hesitancy by showing with a simple animation and comic the complex way vaccines are developed.
Oxford welcomes global pandemic experts for focus on 100 Days Mission
3 November 2023
COVID-19 Department Informing Policy Research Vaccinology
Experts linked to the International Pandemic Preparedness Secretariat (IPPS) visited the University of Oxford’s vaccine laboratories this week as part of a two-day gathering on accelerating pandemic preparedness.
CEPI funding announced for development of vaccine prototype
2 November 2023
Awards & Appointments COVID-19 Research Vaccinology
The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced the launch of a new project to initiate early development of prototype vaccines against the Junín virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly haemorrhagic fevers with epidemic and pandemic potential.
Oxford launches new vaccine trial to enhance design of flu & COVID-19 vaccines
25 October 2023
COVID-19 Clinical Trials Immunology Public Engagement Recruitment Research Vaccinology
A pioneering study into human immunity is being launched today by Oxford Vaccine Group at the University of Oxford. The study, called LEGACY03, is being funded by the Medical Research Council part of UK Research and Innovation. By investigating how lymph nodes work, and how they make responses to vaccines in younger and older people, it has the potential to improve vaccine design for different age groups significantly.
First vaccine trial in older people launched for Middle East Respiratory Syndrome (MERS)
18 September 2023
COVID-19 Clinical Trials Immunology Research Methods Vaccinology
Researchers at the University of Oxford's Pandemic Sciences Institute have launched a new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS).
First in-human trials commence for CCHF vaccine
12 September 2023
COVID-19 Clinical Trials Research Vaccinology
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to human volunteers for the first time. The clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.